Vabysmo (faricimab) is an innovative bispecific antibody drug that simultaneously targets vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), providing a new option for the treatment of retinal diseases.

What Are the Indications for Vabysmo (Faricimab)?

Neovascular (Wet) Age-Related Macular Degeneration (nAMD)

Indicated for patients with neovascular (wet) age-related macular degeneration, a disease characterized by abnormal subretinal blood vessel growth, which is one of the leading causes of severe visual impairment in the elderly.

Diabetic Macular Edema (DME)

Specifically used for the treatment of diabetic macular edema, a common complication in patients with diabetes. It causes blurred central vision due to retinal vascular leakage, severely affecting patients' quality of life.

Macular Edema Following Retinal Vein Occlusion (RVO)

Approved for the treatment of macular edema following retinal vein occlusion, a condition caused by fluid accumulation resulting from obstructed blood flow in the retinal veins.

Dosage Form, Specification, and Properties of Vabysmo (Faricimab)

Dosage Form and Specification

Single-dose prefilled glass syringe: Equipped with a sterile injection filter needle (30G × ½ inch, ultra-thin wall) with an integrated filter.

Single-dose glass vial: Equipped with a sterile 5-micron blunt transfer filter needle (18G × 1½ inches).

Both dosage forms are designed for single-eye treatment and are non-reusable.

Physicochemical Properties

Vabysmo injection is a clear to opalescent, colorless to tan solution.

Each 0.05mL contains 6mg of faricimab-svoa, along with L-histidine (155mcg), L-methionine (52.2mcg), polysorbate 20 (20mcg), sodium chloride (73.1mcg), D-sucrose (2.74mg), and water for injection, with the pH adjusted to 5.5.

Notably, this product does not contain antimicrobial preservatives.

Pre-Use Inspection

A visual inspection must be performed before use to check for the presence of particles, turbidity, or discoloration.

Do not use if these abnormalities are found, or if the packaging, prefilled syringe, vial, or injection filter needle is expired, damaged, or tampered with.

Storage Conditions for Vabysmo (Faricimab)

Routine Storage Requirements

Vabysmo must be stored refrigerated at 2°C to 8°C (36°F to 46°F), with strict avoidance of freezing.

Both prefilled syringes and glass vials should be kept in the original carton to protect from light.

Preparation Before Use

Unopened prefilled syringes or glass vials may be stored at room temperature (20°C to 25°C / 68°F to 77°F) for a maximum of 24 hours.